The Virtual Cell Pharmacology Initiative (VCPI) is an open source platform designed to build a standardized framework for virtual cell models.

Novartis’ $23 billion investment in U.S.-based infrastructure over the next five years is designed to increase manufacturing capacity.

Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.

The study evaluates the long-term cognitive abilities in the mice with over expression of Sox9 or elimination of the gene.

New live-cell DNA damage sensor lets scientists watch repair unfold in real time, potentially opening doors for cancer and aging research.

In a study in IBD patients, scientists observed shifts in gut chemistry, among other changes, that could lead to new treatment strategies.

MagGel-BS platform addresses challenges related to the targeted delivery and subsequent recovery of engineered bacteria within the GI tract.

Two new antibodies may treat autoimmune diseases by reducing inflammation through blocking the immune receptor FcγRI.

PERT edits the genome to permanently express a suppressor tRNA, so that cells affected by nonsense mutations can produce functional protein.

The Biomanufacturing Excellence Act creates a national Center of Excellence to drive innovation in biopharmaceutical ...

Researchers recently enhanced the titer of a cell line still in development to produce adenovirus viral vectors by 7.5-fold, and without the risk of also producing replication-competent adenoviruses ...

U.K. trade group BIA says biopharma has an ethical responsibility to cut carbon emissions, and innovative bioprocessing technologies have a part to play.